Zoetis Inc.

Zoetis Inc. (ZTS) Market Cap

Zoetis Inc. has a market capitalization of —.

No quote data available.

CEO: Kristin C. Peck

Sector: Healthcare

Industry: Drug Manufacturers - General

IPO Date: 2013-02-01

Website: https://www.zoetis.com

Zoetis Inc. (ZTS) - Company Information

Market Cap: -|Sector: Healthcare

Company Profile

Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.

Analyst Sentiment

71%
Buy

From 20 Active Polls

1Y Forecast: $101.50

▲ +0.0% Potential Upside

Consensus Target Metrics

Low Bound

$85

Median

$90

High Bound

$160

Average

$102

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$101.50
▲ +31.32% Upside
Low Target
$85.00
10% Risk
Median Target
$90.00
16% Mid
High Target
$160.00
107% Max

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

Sentiment volume allocation data unavailable.

valuation & financial ratiosdetailed financials

Historical valuation matrix unavailable.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 ZOETIS INC CLASS A (ZTS) — Investment Overview

🧩 Business Model Overview

Zoetis develops, manufactures, and markets animal health products—vaccines, parasiticides, anti-infectives, and specialty therapeutics—sold to veterinary channels and livestock producers through a mix of direct and distributor relationships. The value chain is centered on (1) research and regulatory approval of new products, (2) manufacturing under stringent quality and biosecurity standards, and (3) ongoing demand generation through veterinary practice adoption, established treatment protocols, and repeat purchasing by farms and pet owners.

Customer stickiness is reinforced by clinical and logistical realities: veterinarians and herd managers often standardize on proven products tied to dosing schedules, outcome history, and local formulary habits; resourcing and training to switch products is non-trivial, especially for vaccine programs and prevention protocols.

💰 Revenue Streams & Monetisation Model

Revenue monetisation is driven by a combination of repeat-oriented preventive products and treatment/seasonal demand. Vaccines and parasite control programs tend to create more consistent use patterns (scheduled administration and herd/pet lifecycle management), while anti-infectives and other therapeutics respond to disease incidence and disease management protocols. Monetisation also benefits from portfolio depth: products that share routes to market and veterinary relationships can cross-support each other within the same species segment.

Margin drivers typically include the mix shift toward higher-value biologics/specialty medicines, pricing discipline supported by clinical differentiation, and manufacturing scale efficiencies. Working-capital discipline matters as well because inventory and distribution planning are important in regulated biologics and temperature-sensitive supply chains.

🧠 Competitive Advantages & Market Positioning

Zoetis’ core moat is a combination of regulatory/biological barriers to entry and switching costs created by entrenched veterinary and producer treatment protocols.

  • High barriers to entry (FDA/EMA-style approvals & biologics complexity): Developing vaccines and specialty therapeutics requires sustained R&D, extensive safety/efficacy data packages, and manufacturing know-how. Competitors face time-to-market and approval uncertainty that can deter rapid catch-up.
  • Switching costs via treatment protocols and outcomes: Once a practice or producer adopts a specific prevention/treatment regimen—often built around historical efficacy, dosing timing, and veterinarian recommendations—changing suppliers can increase operational risk and disrupt herd/pet management schedules.
  • Portfolio breadth across species: Coverage across livestock and companion animals supports relationship density with veterinary channels and distributors, reducing reliance on any single product cycle.

Competitive benchmarking: Primary peers include Elanco Animal Health (Eli Lilly), Merck Animal Health (MSD), and Boehringer Ingelheim (Vetmedica). These players compete across vaccines, parasiticides, and therapeutics, but their industry focus and product mix can differ by species emphasis and therapeutic concentration.

Zoetis generally distinguishes itself through broad coverage across major animal categories and a large installed base of veterinary relationships tied to prevention and specialty disease management, while competitors may have more concentrated portfolios or varying strengths by specific disease areas or geographies.

🚀 Multi-Year Growth Drivers

A durable growth path over a 5–10 year horizon can be anchored in several structural themes:

  • Protein demand and livestock productivity: Improving animal health supports higher productivity and feed efficiency, supporting steady demand for vaccines and parasite control products.
  • Companion animal growth and higher per-pet spending: More pets and increased access to veterinary care expand the addressable market for preventive and specialty therapies.
  • Antimicrobial stewardship and prevention-led care: Regulatory and societal pressure to reduce inappropriate antibiotic use increases the relative value of vaccines and parasite control as alternatives for preventing disease outbreaks.
  • Geographic expansion and channel penetration: Distribution development and local regulatory execution can extend product availability and physician/prescriber adoption in underserved regions.
  • Pipeline productivity: Sustained R&D and disciplined portfolio lifecycle management support new product introductions that can offset patent/product-cycle variability.

⚠ Risk Factors to Monitor

  • Regulatory and approval risk: Delays or negative outcomes in the approval process can impact pipeline contribution and timing of launches.
  • Patent and exclusivity pressure: Product lifecycle changes and loss of exclusivity can reduce growth if replacement pipeline execution lags.
  • Efficacy risk and resistance dynamics: For parasiticides and anti-infectives, microbial or parasitic resistance can erode effectiveness and require formulation or next-generation product launches.
  • Supply chain and biologics manufacturing concentration: Concentrated manufacturing capacity, quality incidents, or raw-material constraints can disrupt shipments and increase costs.
  • Pricing and channel dynamics: Wholesaler and distributor contract terms, competitive pricing pressure, and tender dynamics can affect net pricing.

📊 Valuation & Market View

Animal health companies are commonly valued on a blend of earnings power and quality of cash flows, using multiples such as EV/EBITDA and price-to-earnings (or enterprise cash flow measures). The market typically rewards:

  • Portfolio durability (repeatable demand and mix of preventive/specialty products)
  • Pipeline credibility (replacement of exclusivity with new launches)
  • Margin structure (manufacturing efficiency, favorable mix, and pricing discipline)
  • Defensive growth characteristics tied to prevention-led animal health

Multiple compression can occur when investors perceive a weakening pipeline, margin headwinds, or heightened product exclusivity risk.

🔍 Investment Takeaway

Zoetis offers a long-term investment profile supported by difficult-to-replicate regulatory barriers in biologics and specialty therapeutics, combined with real-world switching frictions embedded in veterinary and producer treatment protocols. With multi-species portfolio breadth, prevention-led market tailwinds, and pipeline-driven lifecycle management, Zoetis’ thesis is grounded in durable demand and sustained reinvestment rather than reliance on any single product.


⚠ AI-generated — informational only. Validate using filings before investing.

Related Companies in Healthcare

SOLVENTUM CORP (SOLV)

Healthcare

$14.80B

Mkt Cap

INSULET CORP (PODD)

Healthcare

$11.45B

Mkt Cap

GE HEALTHCARE TECHNOLOGIES INC (GEHC)

Healthcare

$30.72B

Mkt Cap

MOLINA HEALTHCARE INC (MOH)

Healthcare

$10.21B

Mkt Cap

BIO TECHNE CORP (TECH)

Healthcare

$11.29B

Mkt Cap

MODERNA INC (MRNA)

Healthcare

$21.75B

Mkt Cap

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"ZTS reported Q1 2026 revenue of $2.262B and net income of $601M, with EPS of $1.42. On a YoY basis (vs. 2025-03-31), revenue increased to $2.262B from $2.220B (+1.9% YoY) and net income rose to $601M from $631M (-4.8% YoY), indicating earnings softness despite modest top-line growth. QoQ (vs. 2025-12-31), revenue declined from $2.387B to $2.262B (-5.2% QoQ) and net income was roughly flat ($603M to $601M, -0.3% QoQ). Profitability was mixed: gross margin improved (71.66% vs. 68.87% in the prior quarter), but net margin contracted (26.57% vs. 25.26% in Q4 is slightly higher; however, the YoY net margin is down vs. Q1 2025 28.42%). Operating income remained steady at $853M, while the company continued to generate positive operating cash flow ($401M) and positive free cash flow ($291M). Shareholder returns remain supportive through capital returns: ZTS repurchased $606M of shares and paid $224M in dividends during the quarter. Balance sheet resilience appears strong for a consumer/health stock: total assets were $15.15B with equity of $3.23B; net debt stayed negative (net cash position) at about -$1.75B. Total shareholder return is likely pressured by market performance: the stock is down -16.6% over 1Y (price momentum not supportive)."

Revenue Growth

Neutral

Revenue grew modestly +1.9% YoY ($2.220B to $2.262B) but fell -5.2% QoQ ($2.387B to $2.262B), showing a softer sequential trajectory.

Profitability

Fair

Net income declined -4.8% YoY ($631M to $601M). Margins were volatile: gross margin improved to 71.66% from 68.87% QoQ, but net margin is down vs. Q1 2025 (26.57% vs. 28.42%).

Cash Flow Quality

Positive

Operating cash flow was $401M and free cash flow $291M in Q1 2026. Capital returns were meaningful with $606M buybacks and $224M dividends, supported by positive FCF.

Leverage & Balance Sheet

Good

Balance sheet looks resilient: total assets $15.15B; equity $3.23B. Net debt is negative (net cash) at about -$1.75B, indicating low leverage risk.

Shareholder Returns

Neutral

Capital returns were strong (buybacks $606M; dividends $224M), but market performance is a headwind: 1Y price change -16.61% (no >20% momentum).

Analyst Sentiment & Valuation

Fair

Price-to-target appears somewhat conservative: current price $122.38 vs. consensus target $143.5 implies upside, but 1Y performance is negative, suggesting sentiment/expectations have weakened.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

RevenueEarningsP/E RatioSharesDebtMargin %

Fundamentals Overview

Loading fundamentals overview...

Zoetis’ Q1 2026 results show a sharp divergence: International +10% organic operational growth, livestock +12%, and diagnostics +10%, but U.S. companion animal was weak (-11%) and key franchises contracted. Management attributes the slowdown to a non-expanding market where increased competition is price-driven and synchronized with higher pet-owner sensitivity, reduced vet clinic visits, and softer demand for preventative/chronic care. Margin pressure was modest on an underlying basis: adjusted gross margin fell ~10 bps reported, but excluding FX margins improved ~140 bps; the larger reported headwind was ~150 bps unfavorable FX and +3% operating expense growth from labor and freight/logistics. Guidance reflects the same reality: full-year 2026 revenue growth of 2%–5% and adjusted net income growth 2%–6%, with EPS ranges provided. Near-term execution is the pivot—affordability, loyalty options, integrated vet solutions, and improved access—while next-cycle innovation is positioned for value starting end-2027 into 2028.

AI IconGrowth Catalysts

  • International segment delivered 10% organic operational revenue growth; emerging markets in particular showing runway as developed-market headwinds concentrate in the U.S.-like markets.
  • Livestock delivered 12% organic operational revenue growth on $720M revenue, supported by favorable protein demand/producer economics and improved product supply plus commercial wins.
  • Diagnostics growth: companion animal diagnostics revenue grew 10% to $113M, driven by reference lab expansion and growth in chemistry/hematology; contribution from recently launched Vetscan Opticell.
  • Simparica Trio expansion internationally: $76M sales, +29%, driven by key account penetration and launch in Brazil.
  • Feline OA growth driver internationally: Solensia +10% internationally as FeloVax usage increased in China (+13% small animal vaccines products).
  • Science-to-scale execution: shortening time from approval to launch; near-term launches and convenience-led life cycle innovations including long-acting mAbs.

Business Development

  • Agreed to acquire Neogen's animal genomics business to expand livestock genetics capabilities.
  • Referenced partnership/customer/product channel: Vetscan Opticell (Zoetis-launched diagnostics device) supporting diagnostics growth (no external named partner disclosed).
  • Convenia RTU received Canadian approval (product milestone; no named partner disclosed).

AI IconFinancial Highlights

  • Organic operational revenue: flat (reported revenue $2.3B, +3% reported; flat organic). Q1 adjusted net income: $646M, +2% reported and +1% organic.
  • Volume vs price: revenue +2% from price offset by -2% volume (organic operational).
  • International growth: +17% reported and +10% organic operational; U.S. declined -8% reported and -8% organic operational.
  • Companion animal pressure concentrated in U.S.: U.S. companion animal revenue -11%; key dermatology -13% in U.S. ($215M); Apoquel facing competitive price pressure; derm market experiencing declining patient volume.
  • OA Pain mAbs: global -8% to $140M; Librela -13% to $101M; Solensia +6% to $39M (global).
  • Simparica franchise: global -1% to $385M; U.S. -8% ($238M); Simparica Trio -1% globally ($297M) and -8% in U.S.; Simparica -3% globally ($88M).
  • Diagnostics strength: companion animal diagnostics +10% to $113M driven by reference labs and chemistry/hematology expansion.
  • Adjusted gross margin: 71.8%, down ~10 bps (reported). FX unfavorable impact: ~150 bps; excluding FX, margin improved ~140 bps due to price and lower manufacturing costs, partially offset by product/geographical mix.
  • Adjusted operating expenses: +3% operational due to compensation-related expenses plus higher freight/logistics.
  • Adjusted diluted EPS: +7%, including ~3% benefit from convertible debt-funded share repurchases.
  • Guidance (full-year 2026, organic operational): revenue growth 2% to 5%; adjusted net income growth 2% to 6% with range $2.87B to $2.95B.
  • EPS guidance (full-year 2026): reported diluted EPS $6.35 to $6.50; adjusted diluted EPS $6.85 to $7.00.
  • Calendarization tailwind expected: ~200 to 250 bps to revenue growth, but Q1 weakness more than offset it.

AI IconCapital Funding

  • Share repurchases funded via convertible debt: ~3% benefit to adjusted diluted EPS cited as from convertible debt funded share repurchases (specific $ amount not provided).
  • No explicit debt balance or cash runway figures provided in the transcript.

AI IconStrategy & Ops

  • Comprehensive cost and productivity program launched due to softer growth: tighter discretionary spending, procurement/operating efficiencies, and assessment of organizational levers to deliver a leveraged P&L in 2026 and beyond.
  • Commercial execution changes: integrated solutions with veterinarians using broad portfolio; localized action plans in priority markets; targeted DTC activity; loyalty and affordability options to simplify point-of-sale choices and improve authorized access via clinics, retail, and home delivery.
  • Supply chain/availability: reinforcing continuity of supply and responsiveness in key livestock products/markets to prevent demand constraint.
  • Pipeline/innovation prioritization: 12 potential blockbusters; >$7B additional market opportunity; focus on long-acting mAbs and convenience-led life cycle innovations.
  • Near-term product milestone: Canadian approval of Convenia RTU; early phases of Lenivia and Portela launches in certain European markets and Canada; Cytopoint Plus expected to strengthen dermatology leadership.
  • Competitive response: announced/committed near-term actions to compete more effectively while positioning for blocker pipeline delivery beginning significant value in end of 2027 and into 2028.

AI IconMarket Outlook

  • Full-year 2026 updated guidance: revenue growth 2% to 5% (organic operational); adjusted net income growth 2% to 6% ($2.87B to $2.95B).
  • Full-year EPS ranges: reported diluted EPS $6.35 to $6.50; adjusted diluted EPS $6.85 to $7.00.
  • Commentary on phasing: difficult first half comparable periods; expecting improved comparables as the year progresses and widened guidance range due to remaining uncertainty.

AI IconRisks & Headwinds

  • Companion animal market: convergence of higher pet owner price sensitivity (slower clinic price increases but lower clinic traffic) and intensified competition, leading to delayed routine visits and extended dosing; market not expanding despite increased competition.
  • U.S. clinic visit headwind: broader vet clinic dynamic reduced prescription volumes, new patient starts, and compliance (more pronounced in paras and OA Pain).
  • Competition-driven share pressure: dermatology and parasiticides faced additional entrants and aggressive promotions/incentives; generics pressuring vaccines and certain products.
  • Generic competition: Convenia and Cerenia (generic competition impacting both blockbusters) drove meaningful share loss.
  • Retail/distributor purchasing patterns: promotions underperformed expectations; distributor/retail partners took longer to work through opening inventories, engaged in less replenishment, and sales into distributors/retail lagged sales out to customers.
  • FX headwind: ~150 bps unfavorable impact on adjusted gross margins.
  • Guidance sensitivity: persistence of competition and macro uncertainty; management widened guidance range.

Q&A: Analyst Interest

  • Competition vs timeline: Analyst asked how Zoetis can turn the ship near term given competition appears early and may intensify for 1–2 years, with bigger launches farther out. Management cited non-growing markets, share stabilization in paras, Librela stabilization, and near-term execution: affordability-focused DTC, integrated vet solutions, and continued access optimization.
  • Calendarization bridge: Analyst questioned the aggressive full-year ramp despite Q1 being 0% organic under the new math and an implied ~200–250 bps calendar impact. CFO replied guidance already included first-half to second-half dynamics and expects competition/macro persistence to continue; management believes end-market demand normalized vs quarter headwind levels, and widened guidance range.
  • Companion animal quarterly progression & destocking: Analyst asked whether guidance implies distributor/retail restock after destocking, how much of a headwind purchasing patterns/script denials were, and whether retail script denials are reversing to typical conflicts-of-interest behavior. (Transcript cuts off before management’s detailed response.)

Sentiment: CAUTIOUS

Note: This summary was synthesized by AI from the ZTS Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
© 2026 Stock Market Info — Zoetis Inc. (ZTS) Financial Profile